Publicaciones en las que colabora con AMADO ANDRÉS BELMONTE (11)

2024

  1. Severe Presentation of Mpox With Skin, Lung and Pleural Involvement in a Non–HIV-Infected Kidney Transplant Recipient

    American Journal of Kidney Diseases

2022

  1. Cytomegalovirus Exposure and the Risk of Overall Infection After Kidney Transplantation: A Cohort Study on the Indirect Effects Attributable to Viral Replication

    Transplant International, Vol. 35

  2. Genetic polymorphisms in TLR3, IL10 and CD209 influence the risk of BK polyomavirus infection after kidney transplantation

    Scientific Reports, Vol. 12, Núm. 1

  3. Role of cytomegalovirus infection after kidney transplantation on the subsequent risk of atherosclerotic and thrombotic events

    Atherosclerosis Plus, Vol. 48, pp. 37-46

2021

  1. Detection of BK polyomavirus genotypes to predict the development of BK polyomavirus-associated complications in kidney transplant recipients: A retrospective analysis

    Transplant Infectious Disease, Vol. 23, Núm. 4

2020

  1. COVID-19 in solid organ transplant recipients: A single-center case series from Spain

    American Journal of Transplantation, Vol. 20, Núm. 7, pp. 1849-1858

  2. Monitoring of CMV-specific cell-mediated immunity with a commercial ELISA-based interferon-γ release assay in kidney transplant recipients treated with antithymocyte globulin

    American Journal of Transplantation, Vol. 20, Núm. 8, pp. 2070-2080

2009

  1. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients

    Transplant Infectious Disease, Vol. 11, Núm. 5, pp. 400-404

2006

  1. Valganciclovir preemptive therapy for the prevention of cytomegalovirus disease in high-risk seropositive solid-organ transplant recipients

    Transplantation, Vol. 82, Núm. 1, pp. 30-35

2005

  1. Comparison of cytomegalovirus viral load measure by real-time PCR with pp65 antigenemia for the diagnosis of cytomegalovirus disease in solid organ transplant patients

    Transplantation Proceedings

  2. Efficacy and safety of valgancyclovir as preemptive therapy for the prevention of cytomegalovirus disease in solid organ transplant recipients

    Transplantation Proceedings